InChI
1S/2C14H28O2.C6H12N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-8H,1-4H2;/q;;-2;+4/p-2/t;;5-,6-;/m..1./s1
InChI key
DTRJSYSQELJDAW-BLUNCNMSSA-L
SMILES string
CCCCCCCCCCCCCC(O[Pt]1(N[C@@H]2CCCC[C@H]2N1)OC(CCCCCCCCCCCCC)=O)=O
assay
>97.5% (Pt analysis)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Miriplatin (SM-11355) is a platinum (II) complex-based anti-neoplastic agent with increased lipophilicity than its family members cisplatin and carboplatin.
Platinum (II) complex-based anti-neoplastic agent with increased lipophilicity than cisplatin and carboplatin.
存储类别
11 - Combustible Solids
法规信息
新产品
此项目有
Kenji Ikeda et al.
Hepatology research : the official journal of the Japan Society of Hepatology, 47(7), 632-640 (2016-08-04)
The effect of transcatheter arterial chemoembolization (TACE) is not necessarily sufficient in patients with multiple hepatocellular carcinoma (HCC). We evaluated the antitumor activity and adverse events of TACE using warmed miriplatin suspension for multiple HCC. Seventy patients with multiple HCC
Toru Ishikawa et al.
Molecular and clinical oncology, 5(5), 511-516 (2016-11-25)
Transcatheter arterial chemoembolization (TACE) is the standard therapy for Barcelona Clinic Liver Cancer (BCLC) classification intermediate stage B hepatocellular carcinoma (HCC). However, other transcatheter methods, such as transcatheter arterial infusion (TAI), also play an important role in the treatment of
Shan Liu et al.
Journal of pharmaceutical sciences, 105(1), 78-87 (2016-02-09)
Because of the insolubility of miriplatin in water, miriplatin and lipiodol suspension is the sole formulation of miriplatin approved in Japan to treat hepatocellular carcinoma by transcatheter arterial chemoembolization. Until now, there have been no reports of other pharmaceutical formulations
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持